UPDATE: JPMorgan Upgrades Esperion Therapeutics (ESPR) to Neutral Citing 'Achievable Estimates as Outcomes Data Nears'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Esperion Therapeutics (ESPR) PT Raised to $7 at Credit Suisse
May 3, 2022 3:19 PM EDTCredit Suisse analyst Judah Frommer raised the price target on Esperion Therapeutics (NASDAQ: ESPR) to $7.00 (from $6.00) while maintaining a Neutral rating.... More
Esperion Therapeutics (ESPR) Tops Q1 EPS by 11c
May 3, 2022 7:16 AM EDTEsperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.93), $0.11 better than the analyst estimate of ($1.04). Revenue for the quarter came in at $18.8 million versus the consensus estimate of $15.39 million.
For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.
... MoreEsperion Therapeutics (ESPR) Reports Publication of CLEAR Harmony Open-Label Extension Study Data
May 2, 2022 8:01 AM EDTEsperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also known as NEXLETOL®, in the American Journal of Cardiology.
The paper, Long-term Safety and Efficacy of Bempedoic Acid in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (From the CLEAR Harmony Open-Label Extension Study), described the results from the 78-week, Phase 3, OLE study that followed the 52-week CLEAR Harmony Phase 3 study. In the CLEAR Harmony study, patients were randomized 2:1 to... More
